Assembly Bio aspires to deliver finite and curative therapies for chronic hepatitis B virus (HBV) infection, one of the world’s most prevalent and devastating infectious diseases.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
- Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
- Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
- Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
Nov 15, 2022 at 12:35 PM EST
Nov 4 - Nov 8, 2022
Oct 18, 2022 from 12:00 PM to 12:30 PM EDT